MarketPulse
A

$ALMS

3 articles found
3 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Alumis Stock Soars 400% as Cormorant Doubles Down With $8M Bet

Cormorant adds $7.84M to Alumis stake as stock soars 400%. JAK inhibitor candidate envudeucitinib shows strong Phase 3 psoriasis data; lupus readout due Q3 2026.
ALMSTYK2 inhibitorbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

90+ Companies Racing to Transform Psoriasis Treatment Landscape

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.
SNGXTAKFBLGCANFALMS+1clinical trialsbiologics
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Alumis' Psoriasis Drug Shows Strong Phase 3 Results, Paving Way for 2026 FDA Filing

Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.
ALMSquality of lifeTYK2 inhibitor